117 related articles for article (PubMed ID: 10678495)
1. Time-dependent striatal dopamine depletion after injection of 6-hydroxydopamine in the rat. Comparison of single bilateral and double bilateral lesions.
Ben V; Blin O; Bruguerolle B
J Pharm Pharmacol; 1999 Dec; 51(12):1405-8. PubMed ID: 10678495
[TBL] [Abstract][Full Text] [Related]
2. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
Costa G; Abin-Carriquiry JA; Dajas F
Brain Res; 2001 Jan; 888(2):336-342. PubMed ID: 11150495
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain.
Asanuma M; Ogawa N; Nishibayashi S; Kawai M; Kondo Y; Iwata E
Arch Int Pharmacodyn Ther; 1995; 329(2):221-30. PubMed ID: 8540762
[TBL] [Abstract][Full Text] [Related]
4. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
5. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
[TBL] [Abstract][Full Text] [Related]
6. Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease.
Lin L; Meng T; Liu T; Zheng Z
Life Sci; 2013 Mar; 92(4-5):311-6. PubMed ID: 23333823
[TBL] [Abstract][Full Text] [Related]
7. Subacute toluene exposure increases DA dysfunction in the 6-OH dopamine lesioned nigrostriatal dopaminergic system of the rat.
Cintra A; Andbjer B; Finnman UB; Hagman M; Agnati LF; Höglund G; Fuxe K
Neurosci Lett; 1996 Oct; 217(1):61-5. PubMed ID: 8905740
[TBL] [Abstract][Full Text] [Related]
8. Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model.
Fornaguera J; Schwarting RK; Boix F; Huston JP
Synapse; 1993 Feb; 13(2):179-85. PubMed ID: 7680495
[TBL] [Abstract][Full Text] [Related]
9. The grid-walking test: assessment of sensorimotor deficits after moderate or severe dopamine depletion by 6-hydroxydopamine lesions in the dorsal striatum and medial forebrain bundle.
Chao OY; Pum ME; Li JS; Huston JP
Neuroscience; 2012 Jan; 202():318-25. PubMed ID: 22142899
[TBL] [Abstract][Full Text] [Related]
10. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine.
Dluzen D
Brain Res; 1997 Sep; 767(2):340-4. PubMed ID: 9367266
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
12. Enhanced effects of 6-hydroxydopamine on evoked overflow of striatal dopamine in aged rats.
Cass WA; Harned ME; Bailey SL
Brain Res; 2002 May; 938(1-2):29-37. PubMed ID: 12031532
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
[TBL] [Abstract][Full Text] [Related]
14. Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals.
Snyder GL; Keller RW; Zigmond MJ
J Pharmacol Exp Ther; 1990 May; 253(2):867-76. PubMed ID: 2110978
[TBL] [Abstract][Full Text] [Related]
15. The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment.
Mura A; Feldon J; Mintz M
Exp Neurol; 2000 Aug; 164(2):322-32. PubMed ID: 10915571
[TBL] [Abstract][Full Text] [Related]
16. Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice.
Matsuura K; Kabuto H; Makino H; Ogawa N
Neurosci Lett; 1997 Jul; 230(3):191-4. PubMed ID: 9272693
[TBL] [Abstract][Full Text] [Related]
17. Echinacoside prevents the striatal extracellular levels of monoamine neurotransmitters from diminution in 6-hydroxydopamine lesion rats.
Chen H; Jing FC; Li CL; Tu PF; Zheng QS; Wang ZH
J Ethnopharmacol; 2007 Dec; 114(3):285-9. PubMed ID: 17951018
[TBL] [Abstract][Full Text] [Related]
18. The subthalamic activity and striatal monoamine are modulated by subthalamic stimulation.
Yamamoto T; Uchiyama T; Sakakibara R; Taniguchi J; Kuwabara S
Neuroscience; 2014 Feb; 259():43-52. PubMed ID: 24291727
[TBL] [Abstract][Full Text] [Related]
19. In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions.
Chen MT; Morales M; Woodward DJ; Hoffer BJ; Janak PH
Exp Neurol; 2001 Sep; 171(1):72-83. PubMed ID: 11520122
[TBL] [Abstract][Full Text] [Related]
20. The beneficial effect of vanillin on 6-hydroxydopamine rat model of Parkinson's disease.
Abuthawabeh R; Abuirmeileh AN; Alzoubi KH
Restor Neurol Neurosci; 2020; 38(5):369-373. PubMed ID: 32986633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
